Antibiotic (AB) resistance and Clostridium difficile infections (CDI) have become an increasing problem when AB is overused or wrongfully prescribed. Though the right usage of AB therapy is critical in treatment of sepsis and chronic obstructive pulonary disease (COPD). Procalcitonin (PCT) is a biomarker which could indicate whether AB therapy is (still) required in patients with (suspected) sepsis or COPD.
Panaxea has assessed the cost-effectiveness of procalcitonin (PCT) guided AB therapy to reduce AB resistance and CDI in hospitalized patients. Their results can be found in the publication in OMICS.